Wednesday, November 14, 2012

Blow to AstraZeneca - Seroquel XR patent held invalid by German Court

In a press release, AstraZeneca announced that the Federal patent court in Germany has held the formulation patent  protecting Seroquel XR as invalid. The patent was challenged by Accord Healthcare, Hexal (Sandoz), and Teva.  The annual sales of Seroquel XR in Germany is approximately $100m. The patent ruling does not have implications on Seroquel XR patent status in other European countries.

Enter your email address:


Delivered by FeedBurner